Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors.

Anderson ND, de Borja R, Young MD, Fuligni F, Rosic A, Roberts ND, Hajjar S, Layeghifard M, Novokmet A, Kowalski PE, Anaka M, Davidson S, Zarrei M, Id Said B, Schreiner LC, Marchand R, Sitter J, Gokgoz N, Brunga L, Graham GT, Fullam A, Pillay N, Toretsky JA, Yoshida A, Shibata T, Metzler M, Somers GR, Scherer SW, Flanagan AM, Campbell PJ, Schiffman JD, Shago M, Alexandrov LB, Wunder JS, Andrulis IL, Malkin D, Behjati S, Shlien A.

Science. 2018 Aug 31;361(6405). pii: eaam8419. doi: 10.1126/science.aam8419.

PMID:
30166462
2.

Author Correction: EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.

Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, Iniguez AB, Bernard X, Masamsetti VP, Roston S, Lawlor ER, Toretsky JA, Stegmaier K, Lessnick SL, Chen Y, Bishop AJR.

Nature. 2018 Jul;559(7715):E11. doi: 10.1038/s41586-018-0230-z.

PMID:
29950716
3.

A probable primary malignant bone tumor in a pre-Columbian human humerus from Cerro Brujo, Bocas del Toro, Panamá.

Smith-Guzmán NE, Toretsky JA, Tsai J, Cooke RG.

Int J Paleopathol. 2018 Jun;21:138-146. doi: 10.1016/j.ijpp.2017.05.005. Epub 2017 May 26.

PMID:
29778411
4.

Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm.

Tsafou K, Tiwari PB, Forman-Kay JD, Metallo SJ, Toretsky JA.

J Mol Biol. 2018 Aug 3;430(16):2321-2341. doi: 10.1016/j.jmb.2018.04.008. Epub 2018 Apr 12. Review.

PMID:
29655986
5.

EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.

Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, Iniguez AB, Bernard X, Masamsetti VP, Roston S, Lawlor ER, Toretsky JA, Stegmaier K, Lessnick SL, Chen Y, Bishop AJR.

Nature. 2018 Mar 15;555(7696):387-391. doi: 10.1038/nature25748. Epub 2018 Mar 7. Erratum in: Nature. 2018 Jun 27;:.

PMID:
29513652
6.

Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99.

Çelik H, Sciandra M, Flashner B, Gelmez E, Kayraklıoğlu N, Allegakoen DV, Petro JR, Conn EJ, Hour S, Han J, Oktay L, Tiwari PB, Hayran M, Harris BT, Manara MC, Toretsky JA, Scotlandi K, Üren A.

Oncogene. 2018 Apr;37(16):2181-2196. doi: 10.1038/s41388-017-0080-4. Epub 2018 Jan 31.

PMID:
29382926
7.

Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma.

Zöllner SK, Selvanathan SP, Graham GT, Commins RMT, Hong SH, Moseley E, Parks S, Haladyna JN, Erkizan HV, Dirksen U, Hogarty MD, Üren A, Toretsky JA.

Sci Signal. 2017 Oct 3;10(499). pii: eaam8429. doi: 10.1126/scisignal.aam8429.

PMID:
28974650
8.

Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children's Oncology Group and the QuadW Foundation.

Glover J, Man TK, Barkauskas DA, Hall D, Tello T, Sullivan MB, Gorlick R, Janeway K, Grier H, Lau C, Toretsky JA, Borinstein SC, Khanna C, Fan TM; COG Osteosarcoma Biology Group.

PLoS One. 2017 Jul 21;12(7):e0181204. doi: 10.1371/journal.pone.0181204. eCollection 2017.

9.

Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities.

Radic-Sarikas B, Tsafou KP, Emdal KB, Papamarkou T, Huber KV, Mutz C, Toretsky JA, Bennett KL, Olsen JV, Brunak S, Kovar H, Superti-Furga G.

Mol Cancer Ther. 2017 Jan;16(1):88-101. doi: 10.1158/1535-7163.MCT-16-0235. Epub 2016 Nov 15.

10.

Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model.

Minas TZ, Surdez D, Javaheri T, Tanaka M, Howarth M, Kang HJ, Han J, Han ZY, Sax B, Kream BE, Hong SH, Çelik H, Tirode F, Tuckermann J, Toretsky JA, Kenner L, Kovar H, Lee S, Sweet-Cordero EA, Nakamura T, Moriggl R, Delattre O, Üren A.

Oncotarget. 2017 May 23;8(21):34141-34163. doi: 10.18632/oncotarget.9388.

11.

Ezrin Inhibition Up-regulates Stress Response Gene Expression.

Çelik H, Bulut G, Han J, Graham GT, Minas TZ, Conn EJ, Hong SH, Pauly GT, Hayran M, Li X, Özdemirli M, Ayhan A, Rudek MA, Toretsky JA, Üren A.

J Biol Chem. 2016 Jun 17;291(25):13257-70. doi: 10.1074/jbc.M116.718189. Epub 2016 May 2.

12.

Ezrin Enhances EGFR Signaling and Modulates Erlotinib Sensitivity in Non-Small Cell Lung Cancer Cells.

Saygideğer-Kont Y, Minas TZ, Jones H, Hour S, Çelik H, Temel I, Han J, Atabey N, Erkizan HV, Toretsky JA, Üren A.

Neoplasia. 2016 Feb;18(2):111-20. doi: 10.1016/j.neo.2016.01.002.

13.

Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia.

Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen SR, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, Briones M, Carcamo B, Cooper T, Dahl GV, Emanuel PD, Fluchel MN, Goyal RK, Hayashi RJ, Hitzler J, Hugge C, Liu YL, Messinger YH, Mahoney DH Jr, Monteleone P, Nemecek ER, Roehrs PA, Schore RJ, Stine KC, Takemoto CM, Toretsky JA, Costello JF, Olshen AB, Stewart C, Li Y, Ma J, Gerbing RB, Alonzo TA, Getz G, Gruber TA, Golub TR, Stegmaier K, Loh ML.

Nat Genet. 2016 Jan;48(1):101. doi: 10.1038/ng0116-101a. No abstract available.

PMID:
26711114
14.

The genomic landscape of juvenile myelomonocytic leukemia.

Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen S, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, Briones M, Carcamo B, Cooper T, Dahl GV, Emanuel PD, Fluchel MN, Goyal RK, Hayashi RJ, Hitzler J, Hugge C, Liu YL, Messinger YH, Mahoney DH Jr, Monteleone P, Nemecek ER, Roehrs PA, Schore RJ, Stine KC, Takemoto CM, Toretsky JA, Costello JF, Olshen AB, Stewart C, Li Y, Ma J, Gerbing RB, Alonzo TA, Getz G, Gruber T, Golub T, Stegmaier K, Loh ML.

Nat Genet. 2015 Nov;47(11):1326-1333. doi: 10.1038/ng.3400. Epub 2015 Oct 12. Erratum in: Nat Genet. 2015 Nov;47(11):1333. Nat Genet. 2016 Jan;48(1):101.

15.

Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box.

Çelik H, Hong SH, Colón-López DD, Han J, Kont YS, Minas TZ, Swift M, Paige M, Glasgow E, Toretsky JA, Bosch J, Üren A.

Mol Cancer Ther. 2015 Nov;14(11):2497-507. doi: 10.1158/1535-7163.MCT-15-0511. Epub 2015 Sep 10.

16.

Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.

Zöllner SK, Rössig C, Toretsky JA.

Cancer Metastasis Rev. 2015 Sep;34(3):417-28. doi: 10.1007/s10555-015-9575-z. Review.

PMID:
26277104
17.

Ezrin Binds to DEAD-Box RNA Helicase DDX3 and Regulates Its Function and Protein Level.

Çelik H, Sajwan KP, Selvanathan SP, Marsh BJ, Pai AV, Kont YS, Han J, Minas TZ, Rahim S, Erkizan HV, Toretsky JA, Üren A.

Mol Cell Biol. 2015 Sep;35(18):3145-62. doi: 10.1128/MCB.00332-15. Epub 2015 Jul 6.

18.

Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.

Selvanathan SP, Graham GT, Erkizan HV, Dirksen U, Natarajan TG, Dakic A, Yu S, Liu X, Paulsen MT, Ljungman ME, Wu CH, Lawlor ER, Üren A, Toretsky JA.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1307-16. doi: 10.1073/pnas.1500536112. Epub 2015 Mar 3.

19.

High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases.

Hong SH, Tilan JU, Galli S, Izycka-Swieszewska E, Polk T, Horton M, Mahajan A, Christian D, Jenkins S, Acree R, Connors K, Ledo P, Lu C, Lee YC, Rodriguez O, Toretsky JA, Albanese C, Kitlinska J.

Oncotarget. 2015 Mar 30;6(9):7151-65.

20.

RNA helicase A activity is inhibited by oncogenic transcription factor EWS-FLI1.

Erkizan HV, Schneider JA, Sajwan K, Graham GT, Griffin B, Chasovskikh S, Youbi SE, Kallarakal A, Chruszcz M, Padmanabhan R, Casey JL, Üren A, Toretsky JA.

Nucleic Acids Res. 2015 Jan;43(2):1069-80. doi: 10.1093/nar/gku1328. Epub 2015 Jan 6.

21.

A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model.

Rahim S, Minas T, Hong SH, Justvig S, Çelik H, Kont YS, Han J, Kallarakal AT, Kong Y, Rudek MA, Brown ML, Kallakury B, Toretsky JA, Üren A.

PLoS One. 2014 Dec 5;9(12):e114260. doi: 10.1371/journal.pone.0114260. eCollection 2014.

22.

Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.

Tilan JU, Krailo M, Barkauskas DA, Galli S, Mtaweh H, Long J, Wang H, Hawkins K, Lu C, Jeha D, Izycka-Swieszewska E, Lawlor ER, Toretsky JA, Kitlinska JB.

Cancer. 2015 Mar 1;121(5):697-707. doi: 10.1002/cncr.29090. Epub 2014 Nov 11.

23.

Assemblages: functional units formed by cellular phase separation.

Toretsky JA, Wright PE.

J Cell Biol. 2014 Sep 1;206(5):579-88. doi: 10.1083/jcb.201404124. Review.

24.

Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.

Hong SH, Youbi SE, Hong SP, Kallakury B, Monroe P, Erkizan HV, Barber-Rotenberg JS, Houghton P, Üren A, Toretsky JA.

Oncotarget. 2014 Jan 30;5(2):338-50.

25.

Design, synthesis and biological evaluation of ezrin inhibitors targeting metastatic osteosarcoma.

Paige M, Kosturko G, Bulut G, Miessau M, Rahim S, Toretsky JA, Brown ML, Üren A.

Bioorg Med Chem. 2014 Jan 1;22(1):478-87. doi: 10.1016/j.bmc.2013.11.003. Epub 2013 Nov 14.

26.

Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth-inhibitory to growth-promoting effects.

Tilan JU, Lu C, Galli S, Izycka-Swieszewska E, Earnest JP, Shabbir A, Everhart LM, Wang S, Martin S, Horton M, Mahajan A, Christian D, O'Neill A, Wang H, Zhuang T, Czarnecka M, Johnson MD, Toretsky JA, Kitlinska J.

Oncotarget. 2013 Dec;4(12):2487-501.

27.

Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study.

Borinstein SC, Barkauskas DA, Bernstein M, Goorin A, Gorlick R, Krailo M, Schwartz CL, Wexler LH, Toretsky JA.

Pediatr Blood Cancer. 2014 Apr;61(4):749-52. doi: 10.1002/pbc.24778. Epub 2013 Oct 31.

28.

Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.

Lee HJ, Yoon C, Schmidt B, Park DJ, Zhang AY, Erkizan HV, Toretsky JA, Kirsch DG, Yoon SS.

Mol Cancer Ther. 2013 Nov;12(11):2591-600. doi: 10.1158/1535-7163.MCT-13-0338. Epub 2013 Aug 21.

29.

Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.

Carmody Soni EE, Schlottman S, Erkizan HV, Uren A, Toretsky JA.

Clin Orthop Relat Res. 2014 Mar;472(3):874-82. doi: 10.1007/s11999-013-3065-9.

30.

An intrinsically disordered region of the acetyltransferase p300 with similarity to prion-like domains plays a role in aggregation.

Kirilyuk A, Shimoji M, Catania J, Sahu G, Pattabiraman N, Giordano A, Albanese C, Mocchetti I, Toretsky JA, Uversky VN, Avantaggiati ML.

PLoS One. 2012;7(11):e48243. doi: 10.1371/journal.pone.0048243. Epub 2012 Nov 1.

31.

Valosin containing protein (VCP/p97) is a novel substrate for the protein tyrosine phosphatase PTPL1.

Abaan OD, Hendriks W, Uren A, Toretsky JA, Erkizan HV.

Exp Cell Res. 2013 Jan 1;319(1):1-11. doi: 10.1016/j.yexcr.2012.09.003. Epub 2012 Sep 24.

32.

Acetylation Increases EWS-FLI1 DNA Binding and Transcriptional Activity.

Schlottmann S, Erkizan HV, Barber-Rotenberg JS, Knights C, Cheema A, Uren A, Avantaggiati ML, Toretsky JA.

Front Oncol. 2012 Sep 7;2:107. doi: 10.3389/fonc.2012.00107. eCollection 2012.

33.

Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1.

Barber-Rotenberg JS, Selvanathan SP, Kong Y, Erkizan HV, Snyder TM, Hong SP, Kobs CL, South NL, Summer S, Monroe PJ, Chruszcz M, Dobrev V, Tosso PN, Scher LJ, Minor W, Brown ML, Metallo SJ, Üren A, Toretsky JA.

Oncotarget. 2012 Feb;3(2):172-82.

34.

Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.

Smith MA, Kang MH, Reynolds CP, Kurmasheva RT, Alexander D, Billups CA, Toretsky JA, Houghton PJ.

Pediatr Blood Cancer. 2012 Oct;59(4):753-5. doi: 10.1002/pbc.23391. Epub 2012 Feb 7.

35.

Beta-catenin accelerates human papilloma virus type-16 mediated cervical carcinogenesis in transgenic mice.

Bulut G, Fallen S, Beauchamp EM, Drebing LE, Sun J, Berry DL, Kallakury B, Crum CP, Toretsky JA, Schlegel R, Üren A.

PLoS One. 2011;6(11):e27243. doi: 10.1371/journal.pone.0027243. Epub 2011 Nov 7.

36.

Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors.

Erkizan HV, Scher LJ, Gamble SE, Barber-Rotenberg JS, Sajwan KP, Üren A, Toretsky JA.

Cell Cycle. 2011 Oct 1;10(19):3397-408. doi: 10.4161/cc.10.19.17734. Epub 2011 Oct 1.

37.

VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells.

Ringer L, Sirajuddin P, Heckler M, Ghosh A, Suprynowicz F, Yenugonda VM, Brown ML, Toretsky JA, Uren A, Lee Y, MacDonald TJ, Rodriguez O, Glazer RI, Schlegel R, Albanese C.

Cancer Biol Ther. 2011 Nov 1;12(9):818-26. doi: 10.4161/cbt.12.9.17682. Epub 2011 Nov 1.

38.

Mutational inactivation of STAG2 causes aneuploidy in human cancer.

Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, Toretsky JA, Rosenberg SA, Shukla N, Ladanyi M, Samuels Y, James CD, Yu H, Kim JS, Waldman T.

Science. 2011 Aug 19;333(6045):1039-43. doi: 10.1126/science.1203619.

39.

Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells.

Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW, Glasgow E, Dakshanamurthy S, Lee HS, Daar I, Toretsky JA, Khanna C, Uren A.

Oncogene. 2012 Jan 19;31(3):269-81. doi: 10.1038/onc.2011.245. Epub 2011 Jun 27.

40.

Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors: implications for tumor biology and therapy.

Lu C, Tilan JU, Everhart L, Czarnecka M, Soldin SJ, Mendu DR, Jeha D, Hanafy J, Lee CK, Sun J, Izycka-Swieszewska E, Toretsky JA, Kitlinska J.

J Biol Chem. 2011 Aug 5;286(31):27494-505. doi: 10.1074/jbc.M111.224089. Epub 2011 Jun 16.

41.

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.

Rahim S, Beauchamp EM, Kong Y, Brown ML, Toretsky JA, Üren A.

PLoS One. 2011 Apr 29;6(4):e19343. doi: 10.1371/journal.pone.0019343.

42.

Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: a report from the Children's Oncology Group.

Borinstein SC, Barkauskas DA, Krailo M, Scher D, Scher L, Schlottmann S, Kallakury B, Dickman PS, Pawel BR, West DC, Womer RB, Toretsky JA.

Cancer. 2011 Nov 1;117(21):4966-76. doi: 10.1002/cncr.26112. Epub 2011 Apr 8.

43.

Hunting ALK to feed targeted cancer therapy.

Wellstein A, Toretsky JA.

Nat Med. 2011 Mar;17(3):290-1. doi: 10.1038/nm0311-290. No abstract available.

44.

Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.

Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, Peaceman D, Ozdemirli M, Rodriguez O, Macdonald TJ, Albanese C, Toretsky JA, Uren A.

J Clin Invest. 2011 Jan;121(1):148-60. doi: 10.1172/JCI42874. Epub 2010 Dec 22.

45.

High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.

Awad O, Yustein JT, Shah P, Gul N, Katuri V, O'Neill A, Kong Y, Brown ML, Toretsky JA, Loeb DM.

PLoS One. 2010 Nov 11;5(11):e13943. doi: 10.1371/journal.pone.0013943.

46.

Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

Lu C, Everhart L, Tilan J, Kuo L, Sun CC, Munivenkatappa RB, Jönsson-Rylander AC, Sun J, Kuan-Celarier A, Li L, Abe K, Zukowska Z, Toretsky JA, Kitlinska J.

Oncogene. 2010 Oct 14;29(41):5630-42. doi: 10.1038/onc.2010.301. Epub 2010 Aug 2.

47.

Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.

Erkizan HV, Uversky VN, Toretsky JA.

Clin Cancer Res. 2010 Aug 15;16(16):4077-83. doi: 10.1158/1078-0432.CCR-09-2261. Epub 2010 Jun 14. Review.

48.

IGF-1R targeted treatment of sarcoma.

Toretsky JA, Gorlick R.

Lancet Oncol. 2010 Feb;11(2):105-6. doi: 10.1016/S1470-2045(09)70391-2. Epub 2009 Dec 23. No abstract available.

PMID:
20036195
49.

Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia.

Raygada M, Arthur DC, Wayne AS, Rennert OM, Toretsky JA, Stratakis CA.

Pediatr Blood Cancer. 2010 Jan;54(1):173-5. doi: 10.1002/pbc.22297.

50.

Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.

Stylianou DC, Auf der Maur A, Kodack DP, Henke RT, Hohn S, Toretsky JA, Riegel AT, Wellstein A.

Oncogene. 2009 Sep 17;28(37):3296-306. doi: 10.1038/onc.2009.184. Epub 2009 Jul 27.

Supplemental Content

Loading ...
Support Center